Cryoport-Systems-Logo-Final NOV2020 - png-1             BioLife_logo_solidrings


Cryoport has entered into a strategic relationship with BioLife Plasma Services, part of the global biopharmaceutical company, Takeda Pharmaceutical Company Limited, to provide consistent, high-quality cellular starting material for use in the manufacture of life-saving cellular therapies.

By bringing together BioLife Plasma Services’ proficiency, experience and infrastructure in the automated collection of regulated blood components for further processing with Cryoport’s life sciences’ world-class capabilities and expertise in temperature-controlled supply chain solutions, the companies aim to establish a standardized, integrated apheresis collection, processing, storage and distribution solution for cellular therapies. Importantly, the new platform will leverage the cryo-processing expertise of Cell Matters, which Cryoport acquired in July 2022. The solution platform will be integrated be under one contract, quality management system (QMS) and audit process and will seek to de-risk the supply chain of leukapheresis to enable robust manufacturing of cellular therapies.

The relationship, which will facilitate compliance with GMP regulations, aims to shorten processing and logistics time and standardize collections, contracting, and equipment, in turn, enabling researchers and developers to accelerate cellular therapy programs.

Increased access to apheresis, with efficient, scalable and reliable end-to-end processes will benefit not only donors and patients, but manufacturers and the providers of these life-saving therapies.


To read this full story, check out our Press Release:

To schedule a meeting to learn more about the platform and the benefits it can provide, please fill out the form below.

Cryoport® is a trademark of Cryoport, Inc. and used with permission by Cryoport Systems, LLC